United Therapeutics CEO Exercises Options & Sells $4.86M in UTHR via 10b5-1 Plan

Insider Transaction Overview

On August 31, 2026, Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp ($UTHR), executed an option exercise and corresponding sale of 9,500 shares of common stock.

Key Details:

• Derivative Execution: Exercised 9,500 stock options with an exercise price of $135.42 per share.
• Sale Execution: Sold 9,500 shares across multiple open-market tranches ranging from $507.84 to $514.96, generating total gross proceeds of ~$4,855,312.39 (weighted average sale price of approximately $511.09 per share).
• Ownership Status: Shares were held indirectly by a family trust. Post-transaction, the trust retains 324,443 shares of common stock, alongside other direct and indirect holdings across family trusts and direct holdings.
• 10b5-1 Plan: The transaction was executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025.

Significance Assessment

Given that this was a routine option exercise and sale completed under an established Rule 10b5-1 plan ahead of option expiration in March 2027, the trading significance is categorized as Low.